Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacarbazine +/- Oblimersen in Advanced Malignant Melanoma
NCT00016263Phase 3Completed
- Sponsor
- Genta Incorporated
- Start
- Jul 2000
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 3 trial of oblimersen in Malignant Melanoma (MM), sponsored by Genta Incorporated. Started Jul 2000; status: completed.
02
Drugs
oblimersen
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00016263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016263.